BioLineRx Ltd. transitioned from direct commercialization to a development-focused strategy by out-licensing its lead product APHEXDA (motixafortide) rights globally except Asia and for solid tumors. After revenue peaked in 2024 due to upfront and milestone payments, it sharply declined in 2025 as sales operations ceased, with revenues near $1.2 million. The company now focuses on advancing motixafortide in solid tumors, including pancreatic cancer trials, and developing new oncology and rare disease assets through in-licensing. Net losses narrowed in 2025 due to lower operating expenses, but sustainability depends heavily on milestone and royalty income from partners and additional capital raises.